KRAS and non-small cell lung carcinoma: AURKA has been implicated in the tumorigenesis of KRAS mutant NSCLC as well [46], which encouraged the combinatory use of the AURKA inhibitor, VIC-1911, with sotorasib for KRAS G12C mutant NSCLC [47].